Loading stock data…
GH
$130.12+5.23 (+4.19%)
After Hours$127.61-2.51 (-1.93%)· Last close Jun 9
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Guardant Health, Inc. in the Healthcare sector is trading at $130.12. Wall Street consensus targets $137.09 (22 analysts), implying a +5.4% move over the next 12 months. The stock is currently near its 52-week high of $134.28, remaining 42.1% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$130.12
Potential Downside
0%
Whystock Fair Value$130.12
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus22 analysts
Mean target$137.09+5.4%
Range$90.00 – $190.00
Fundamentals
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liqu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
239.24%
Volume
Today's trading volume
2.26M
Recent News
How The Guardant Health (GH) Investment Story Is Evolving As Expectations Stay Unchanged
Guardant Health’s latest analyst update keeps the stock’s price target unchanged, indicating that current expectations remain steady for now. In the following sections, you will see how to track this kind of unchanged price target alongside other updates so you can stay on top of the evolving narrative around Guardant Health. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space...
Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls
Tesla upgraded, Lululemon downgraded: Wall Street's top analyst calls
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.
A new blood test can help detect colon cancer, but it’s not as good as the test you hate to take
About 50 million Americans aren’t getting screened for colon cancer at a time when colon-cancer rates are rising.
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.